Universe Pharmaceuticals INC (UPC) — 6-K Filings

6-K Filings (22)

• Universe Pharmaceuticals INC Holds 2025 Annual Shareholder Meeting — Sep 3, 2025 Risk: low
  Universe Pharmaceuticals INC held its reconvened 2025 Annual General Meeting of Shareholders on September 2, 2025, in Ji'an, Jiangxi, China. The meeting, origin
• Universe Pharmaceuticals Meeting Adjourned Due to Lack of Quorum — Aug 26, 2025 Risk: low
  Universe Pharmaceuticals INC convened its 2025 annual general meeting on August 26, 2025, but it was adjourned due to a lack of quorum. The meeting has been res
• Universe Pharmaceuticals Schedules 2025 Shareholder Meeting — Jul 29, 2025 Risk: low
  Universe Pharmaceuticals INC is holding its 2025 Annual General Meeting of Shareholders on July 29, 2025. The company has furnished a Notice and Proxy Statement
• Universe Pharmaceuticals Reports Q1/Q2 Revenue Drop — Jul 3, 2025 Risk: medium
  Universe Pharmaceuticals INC reported financial results for the six months ended March 31, 2025. Revenues decreased by 29.0% to $9.2 million compared to $12.9 m
• Universe Pharmaceuticals Announces Share Consolidation — Mar 20, 2025 Risk: low
  Universe Pharmaceuticals INC announced a share consolidation, effective March 20, 2025. This move aims to adjust the number of outstanding ordinary shares, with
• Universe Pharmaceuticals INC Holds Shareholder Meeting — Mar 11, 2025 Risk: low
  Universe Pharmaceuticals INC held an extraordinary general meeting of shareholders on March 8, 2025, which was a re-convening of a meeting originally scheduled
• Universe Pharmaceuticals Adjourns Shareholder Meeting — Mar 3, 2025 Risk: medium
  Universe Pharmaceuticals INC convened an extraordinary general meeting of shareholders on March 1, 2025. Due to a lack of quorum, the meeting was adjourned to M
• Universe Pharmaceuticals Gets Nasdaq Delisting Warning — Feb 25, 2025 Risk: high
  Universe Pharmaceuticals INC filed a Form 6-K on February 25, 2025, reporting a staff determination notice from Nasdaq concerning its delayed annual report. The
• Universe Pharmaceuticals INC Holds Shareholder Meeting — Feb 20, 2025 Risk: low
  Universe Pharmaceuticals INC held an extraordinary general meeting of shareholders on February 19, 2025, which was a re-convening of a meeting originally schedu
• Universe Pharmaceuticals Adjourns Shareholder Meeting Due to Lack of Quorum — Feb 18, 2025 Risk: medium
  Universe Pharmaceuticals INC convened an extraordinary general meeting of shareholders on February 17, 2025. Due to a lack of quorum, the meeting was adjourned
• Universe Pharmaceuticals Files 6-K Report — Feb 11, 2025 Risk: low
  Universe Pharmaceuticals INC, incorporated in the Cayman Islands, filed a Form 6-K on February 11, 2025. The filing is a report of a foreign private issuer for
• Universe Pharmaceuticals Receives Nasdaq Delisting Notice — Feb 3, 2025 Risk: high
  Universe Pharmaceuticals INC received a Nasdaq delisting notice on February 3, 2025, indicating potential delisting from the Nasdaq Capital Market. The company
• Universe Pharmaceuticals Schedules Shareholder Meeting for Jan 2025 — Jan 30, 2025 Risk: low
  Universe Pharmaceuticals INC announced an Extraordinary General Meeting of Shareholders to be held in January 2025. The meeting will discuss and vote on propose
• Universe Pharmaceuticals Sells 388,000 Shares — Dec 12, 2024 Risk: medium
  On December 6, 2024, Universe Pharmaceuticals INC entered into a Securities Purchase Agreement to issue and sell 388,000 ordinary shares. The company is a Cayma
• Universe Pharmaceuticals Announces Share Consolidation — Nov 13, 2024 Risk: medium
  Universe Pharmaceuticals INC announced a share consolidation, effective November 13, 2024. This move aims to adjust the number of outstanding ordinary shares to
• Universe Pharmaceuticals Gets Nasdaq Bid Price Warning — Nov 1, 2024 Risk: medium
  Universe Pharmaceuticals INC received a notification from Nasdaq on November 1, 2024, indicating a deficiency in meeting the minimum bid price requirement. The
• Universe Pharmaceuticals Appoints New Auditor — Oct 10, 2024 Risk: low
  Universe Pharmaceuticals INC (Nasdaq: UPC) announced on October 8, 2024, the appointment of Enrome LLP as its new independent registered public accounting firm.
• Universe Pharmaceuticals Holds 2024 Annual Meeting, Approves Proposals — Sep 27, 2024 Risk: low
  Universe Pharmaceuticals INC held its 2024 Annual General Meeting on September 27, 2024, where shareholders approved all nine proposals presented. The meeting t
• Universe Pharmaceuticals Files 6-K Report — Sep 20, 2024 Risk: low
  Universe Pharmaceuticals INC filed a Form 6-K on September 20, 2024, reporting for the period ending March 31, 2024. The filing is a report of a foreign private
• Universe Pharmaceuticals Files 6-K for August 2024 AGM — Sep 3, 2024 Risk: low
  Universe Pharmaceuticals INC filed a Form 6-K on September 3, 2024, for the month of August 2024. The filing is related to the company's 2024 Annual General Mee
• Universe Pharmaceuticals Closes Public Offering — Jul 18, 2024 Risk: medium
  Universe Pharmaceuticals INC announced the closing of its self-underwritten public offering on July 15, 2024. The company sold 20,000,000 ordinary shares at a p
• Universe Pharma Transfers to Nasdaq Capital Market, Avoids Delisting — Feb 7, 2024
  Universe Pharmaceuticals INC, a Chinese pharmaceutical company, successfully transferred its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX